Phenotypic changes in neutrophils after rhG-CSF administration in non-Hodgkin's lymphoma patients undergoing PBSC transplantation or conventional chemotherapy.
Carulli
G
G
Papineschi
F
F
Benedetti
E
E
Vanacore
R
R
Azzarà
A
A
Petrini
M
M
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002634:Chemotaxis, Leukocyte / Q000187:drug effects / Q000502:physiology; D003131:Combined Modality Therapy; D005260:Female; D000069585:Filgrastim; D016179:Granulocyte Colony-Stimulating Factor / Q000494:pharmacology*; D006684:HLA-DR Antigens / Q000032:analysis*; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D016130:Immunophenotyping; D008163:Luminescent Measurements; D008228:Lymphoma, Non-Hodgkin / Q000097:blood* / Q000188:drug therapy / Q000628:therapy; D008297:Male; D015260:Neprilysin / Q000032:analysis* / Q000502:physiology; D009504:Neutrophils / Q000737:chemistry / Q000187:drug effects* / Q000502:physiology; D010587:Phagocytosis; D011994:Recombinant Proteins; D016897:Respiratory Burst
D006684:HLA-DR Antigens; D011994:Recombinant Proteins; D016179:Granulocyte Colony-Stimulating Factor; D015260:Neprilysin; D000069585:Filgrastim